Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00683332|
Recruitment Status : Completed
First Posted : May 23, 2008
Results First Posted : July 8, 2011
Last Update Posted : July 8, 2011
|Condition or disease||Intervention/treatment|
|Complicated Skin and Skin Structure Infections Complicated Intra-abdominal Infections||Drug: Tigecycline (Tygacil)|
|Study Type :||Observational|
|Actual Enrollment :||621 participants|
|Official Title:||A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)|
|Study Start Date :||April 2007|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
Drug: Tigecycline (Tygacil)
This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
- Number of Participants With Spontaneous Adverse Events [ Time Frame: 30 days post injection up to 3 years ]Adverse events were based on the signs or symptoms detected during the physical examination and on clinical evaluation of the participant. In addition to the information obtained from these sources, the participant was asked the following nonspecific question: "How have you been feeling since your last visit?"
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00683332
|Pfizer Investigational Site|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|